ChETYRE ASPEKTA AD\"YuVANTNOY TARGETNOY TERAPII HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZY


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Several phase III clinical trials have studied the effect of trastuzumab in combination with chemotherapy on recurrence-free survival in patients with HER2-positive breast cancer, depending on the type of chemotherapy, duration of trastuzumab treatment and time of the its addition to the chemotherapy. All the major clinical studies have demonstrated the continued benefit of the one-year treatment with trastuzumab in addition to standard anthracycline/taxane-based chemotherapy.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

V. Semiglazov

V. Semiglazov

Әдебиет тізімі

  1. Жукова Л.Г., Личиницер М.Р. Адъювантная терапия трастузумабом при ранних стадиях рака молочной железы: 12 или 24 месяца (по данным ESMO, Вена, октябрь 2012) // Фарматека 2012. № 18. С. 69-70.
  2. Семиглазов В.Ф., Семиглазов В.В., Манихас А.Г. Рак молочной железы. Химиотерапия и таргетная терапия. М., 2012. 360 с.
  3. Owens M.A., Horten B.C., Da Silva M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-9.
  4. Sjogren S., Inganas M., Lindgren A., et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998;16:462-69.
  5. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
  6. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
  7. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of Clin Oncol 2009;27:1999-2006.
  8. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
  9. Perez E.A., Romond E.H., Suman V.J., et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2- positive breast cancer. J Clin Oncol 2007;25:6s (suppl 18S, abstr 512).
  10. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
  11. Slamon D.J., Eiermann W., Robert N.J., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients: BCIRG006 study. Cancer Res 2009;69:500s (abstr 62).
  12. Piccart-Gebhart M.J., Procter M., Leyland- Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
  13. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-74.
  14. Perez E.A. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 2009;114:195-201.
  15. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
  16. von Minckwitz G., du Bois A., Schmidt M., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J 2005;353:1659-72.
  17. Smith I., Procter M., Gelber R.D., et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007; 369:29-36.
  18. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-19.
  19. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231-38.
  20. Rastogi P., Jeong J., Geyer C.E., et al. Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC) - paclitaxel (T) compared to AC-T with trastuzumab (H). J Clin Oncol 2007;25:6s (suppl 18S, abstr LBA513).
  21. Russell S.D., Blackwell K.L., Lawrence J., et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: Acombined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010;28:3416-21.
  22. Procter M., Suter T.M., de Azambuja E., et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010;28: 3422-28.
  23. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-84.
  24. Perez E., Romond E., Suman V. et al. Four - year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor 2 - positive breast cancer: joint analysis of data from NCCTG N 9831 and NSABP B-31. J Clin Oncolog 2011;29:3366-73.
  25. Slamon D., Eiermann W., Robert N., et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med 2011;365:1273-83.
  26. Pivot X., Romieu G., Bonnefoi H., et al. PHARE trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Cancer Res 2012;72(24 Suppl):104s.
  27. Goldhirsch A., Piccart-Gebhart M., Procter M., et al. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Cancer Res 2012;72(24 Suppl):103s.
  28. Goldhirsch A. Personalized adjuvant therapies: lessons from the past. The Breast 2013;22(suppl):S1 [abst. 01].
  29. Piccart M., Pinto A. Patients with HER2-positive breast cancer: delivery, duration and combination therapies.The breast 22 (suppl):S16-S17 [abst. SP 9.04].
  30. De Cock E., Semiglazov V., Vivanco G., et al. Time savings with trastuzumab subcutaneous vs intravenous administration: a time and motion study. The breas 22(suppl):S8 [abst. P209].

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2013

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>